¡Ya estamos en ! Descubre más

Maze Therapeutics

MAZE

Capitalización de mercado USD 1529 M

27.53 USD

+0.05

0.18%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

27.53

0.00

0%

1 día

0.18%

5 días

1.55%

1 mes

15.09%

3 meses

1.32%

6 meses

2.46%

En lo que va del año

-30.78%

1 año

-3.23%

5 años

72.6%

10 años

72.6%

Acerca de: Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Empleados: 141

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 45.5%

Neutral 45.5%

Negativo 9.1%

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held October 21–25, 2026, in Denver, Colorado.

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Investors Business Daily

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

The Motley Fool

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex's inaxaplin; pivotal trials are planned for 1H 2027.

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics Announces Appointments to Its Board of Directors

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience

Maze Therapeutics Announces Appointments to Its Board of Directors

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second quarter ended June 30, 2026, highlighting recent progress and business updates.

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™